Platinum Membership for 'International Consortium for Clinical Data Standards (CDISC)'
JNPMEDI
JNPMEDI has acquired a platinum membership of the "Clinical Data Interchange Standard Consortium (CDISC)." JNPMEDI's acquisition of CDISC Platinum membership means that it guarantees that it can provide clinical trial results that meet international standards to customers by operating clinical trials based on CDISC standards.
Platinum Membership for 'International Consortium for Clinical Data Standards (CDISC)'
JNPMEDI, a medical data platform company, announced on the 7th that it has acquired platinum membership for the "Clinical Data Interchange Standard Consortium (CDISC)."
Ensuring the provision of clinical trial results that meet international standards through the "Maven Clinical Cloud."
We will gradually expand the area of clinical trial data service applied to CDISC standards and take the lead in streamlining clinical trials.
CDISC is an international non-profit organization that defines the standard format of clinical trial data. Regulatory agencies such as the U.S. FDA, Europe EMA, and Japan's PMDA require CDISC to apply standard formats, implementing new medicines, medical devices, and medical technology approval procedures, and managing clinical data according to CDISC standards. Accordingly, global pharmaceutical companies and research institutes are submitting clinical trial data to regulatory agencies in accordance with CDISC standards.
JNPMEDI’s acquisition of CDISC Platinum membership means that it guarantees that it can provide customers with clinical trial results that meet international standards by operating clinical trials based on CDISC standards. As a result, customers using JNPMEDI's "Maven Clinical Cloud" can manage data by applying international standards at a reasonable cost.
Maven Clinical Cloud is a SaaS-based solution that can be used by selecting only the necessary services, enabling more efficient clinical trial data management and analysis based on CDISC International Clinical Data Standards.
Meanwhile, JNPMEDI will participate as a platinum member in CDISC Interchange events in Korea, the United States, Europe, and Japan, and it plans to attend 2023 US Interchange in October this year as a solo booth to showcase its solution to global customers.
As CDISC is becoming an essential element in digitizing clinical trial data, companies are increasingly concerned about submitting the format, said CEO Kwun-ho Jeong. "We expect to accelerate the global standardization and service expansion of Maven Clinical Cloud by acquiring CDISC Platinum membership."